Table 3.
Characteristics of chelating agents used in clinical practice.
| Route of administration | Adult dose | Route of metal complex excretion | Side effects | |
|---|---|---|---|---|
| BAL | IM | 5 mg/kg/day | Urine, bile, faeces, lungs | Nausea, vomiting, hypertension, tachycardia, headache |
|
| ||||
| Deferiprone | Oral | 50–100 mg/kg/day | Urine | CNS toxicity, lenticular opacities, arthropathy |
|
| ||||
| Deferoxamine | IV | 50 mg/kg/day | Urine | Nausea, weight loss, ocular toxicity |
| Subcutaneously | 20 mg/kg/day | |||
|
| ||||
| Deferasirox | Oral | 35 mg/kg/day | Faeces, urine | Abdominal pain, nausea, vomiting, elevation of liver enzymes |
|
| ||||
| DMPS | Oral | 300 mg three times a day | Urine | Rash, nausea, leukopenia |
| IV | until 1500 mg/day | |||
| IM | 20 mg/kg/day | |||
|
| ||||
| DMSA | Oral | 30 mg/kg/day | Urine, bile, faeces, lungs | Gastrointestinal disorders (GI), skin rashes, flu-like symptoms |
| IV | 10 mg/kg three times a day | |||
|
| ||||
| EDTA | IV | 2 gr/week | Urine | None∗ |
|
| ||||
| D-Penicillamine | Oral | 5–20 mg/kg/day | Urine | Degenerative dermopathy, thromboleukocytopenia, GI |
∗When used once a week at the dose reported and intravenously injected in about 2 hours.
DMPS: 2,3-dimercapto-1-propane sulphonic acid.
DMSA: meso-2,3-dimercaptosuccinic acid.
EDTA: CaNa2 ethylenediaminetetraacetic acid.